Skip to main content
main-content
Erschienen in: CardioVasc 1/2021

18.02.2021 | Hypertonie in der Kardiologie | Zertifizierte Fortbildung

Update Hypertonie

Ab wann und wie behandeln?

verfasst von: Prof. Dr. med. Ulrich Kintscher

Erschienen in: CardioVasc | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Auszug

Obwohl sich die Versorgung der Patienten*innen mit arterieller Hypertonie in den letzten Jahren verbessert hat, sind immer noch große Teile der Betroffenen nicht adäquat behandelt, und es liegt eine geringe Therapieadhärenz vor. Ab einem Blutdruckwert von ≥ 140/90 mmHg sollte die Behandlung begonnen werden. …
Literatur
1.
Zurück zum Zitat Collaborators GBDRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659-724 Collaborators GBDRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659-724
2.
Zurück zum Zitat Neuhauser HK, Adler C, Rosario AS et al. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. J Hum Hypertens. 2015;29:247-53 Neuhauser HK, Adler C, Rosario AS et al. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. J Hum Hypertens. 2015;29:247-53
3.
Zurück zum Zitat Collaboration NCDRF. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394:639-51 Collaboration NCDRF. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394:639-51
4.
Zurück zum Zitat Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26:824-35 Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26:824-35
5.
Zurück zum Zitat Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104 Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104
6.
Zurück zum Zitat Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269-324 Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269-324
7.
Zurück zum Zitat Lonn EM, Bosch J, Lopez-Jaramillo P et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374:2009-20 Lonn EM, Bosch J, Lopez-Jaramillo P et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374:2009-20
8.
Zurück zum Zitat Brunstrom M, Carlberg B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178:28-36 Brunstrom M, Carlberg B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178:28-36
9.
Zurück zum Zitat Wright JT, Jr., Williamson JD, Whelton PK et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-16 Wright JT, Jr., Williamson JD, Whelton PK et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-16
10.
Zurück zum Zitat Kjeldsen SE, Lund-Johansen P, Nilsson PM et al. Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. Hypertension. 2016;67:808-12 Kjeldsen SE, Lund-Johansen P, Nilsson PM et al. Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. Hypertension. 2016;67:808-12
11.
Zurück zum Zitat Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;1125(9):882-7.e1 Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;1125(9):882-7.e1
12.
Zurück zum Zitat Gupta P, Patel P, Strauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017;69:1113-20 Gupta P, Patel P, Strauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017;69:1113-20
13.
Zurück zum Zitat Poulter NR, Borghi C, Parati G et al. Medication adherence in hypertension. J Hypertens. 2020;38(4):579-87 Poulter NR, Borghi C, Parati G et al. Medication adherence in hypertension. J Hypertens. 2020;38(4):579-87
14.
Zurück zum Zitat Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407 Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407
15.
Zurück zum Zitat Rea F, Corrao G, Merlino L et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39:3654-61 Rea F, Corrao G, Merlino L et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39:3654-61
16.
Zurück zum Zitat Williams B, Macdonald TM, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-68 Williams B, Macdonald TM, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-68
17.
Zurück zum Zitat https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-hydrochlorothiazid.html Zugriff: 25.2.2020 https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-hydrochlorothiazid.html Zugriff: 25.2.2020
18.
Zurück zum Zitat Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-81.e9 Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-81.e9
19.
Zurück zum Zitat Pottegard A, Hallas J, Olesen M et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282:322-31 Pottegard A, Hallas J, Olesen M et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282:322-31
20.
Zurück zum Zitat https://www.akdae.de/Stellungnahmen/Weitere/20181220.pdf Zugriff: 25.2.2020 https://www.akdae.de/Stellungnahmen/Weitere/20181220.pdf Zugriff: 25.2.2020
21.
Zurück zum Zitat https://dgk.org/thema/hct/ Zugriff: 25.2.2020 https://dgk.org/thema/hct/ Zugriff: 25.2.2020
22.
Zurück zum Zitat https://www.hochdruckliga.de/pressemeldung/items/diuretikum-hydrochlorothiazid-hct-erhoeht-das-risiko-fuer-weissen-hautkrebs.html Zugriff: 25.2.2020 https://www.hochdruckliga.de/pressemeldung/items/diuretikum-hydrochlorothiazid-hct-erhoeht-das-risiko-fuer-weissen-hautkrebs.html Zugriff: 25.2.2020
Metadaten
Titel
Update Hypertonie
Ab wann und wie behandeln?
verfasst von
Prof. Dr. med. Ulrich Kintscher
Publikationsdatum
18.02.2021
Verlag
Springer Medizin
Erschienen in
CardioVasc / Ausgabe 1/2021
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI
https://doi.org/10.1007/s15027-020-3454-4